GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modalis Therapeutics Corp (TSE:4883) » Definitions » Future Policy Benefits

Modalis Therapeutics (TSE:4883) Future Policy Benefits


View and export this data going back to 2020. Start your Free Trial

What is Modalis Therapeutics Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.


Modalis Therapeutics (TSE:4883) Business Description

Traded in Other Exchanges
N/A
Address
16-5 Nihombashi-Kabuto-cho, Chuo-ku, Tokyo, JPN, 103-0026
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.